Immunome

Immunome, Inc. is a biopharmaceutical company, which engages in the discovery and development of antibody therapeutics products. It focuses on oncology and infectious disease areas. It utilizes the proprietary human memory B cell platform to enable the discovery of novel antibodies in both these therapeutic areas because of the interrogation of memory B cells from patients who have learned to fight off these diseases. The company was founded by Scott K. Dessain and Gregory P. Licholai on March 2, 2006 and is headquartered in Exton, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Immunome, Inc. is a biopharmaceutical company, which engages in the discovery and development of antibody therapeutics products. It also focuses on oncology and infectious disease areas. The company was founded by Scott K. Dessain and Gregory P. Licholai on March 2, 2006 and is headquartered in Bothell, WA.

Shares of Immunome Inc. blasted 212.6% higher toward new highs Thursday, to pace all of the premarket gainers trading on major U.S. exchanges, after biopharmaceutical company said it has isolated potent antibodies that are capable of neutralizing several SARS-CoV-2 variants, including the South African Variant (B.1.351) in pseudovirus testing. Trading volume was about 506,600 shares, compared with the full-day average of about 117,600 shares.

Immunome stock more than triples after isolating antibodies in treatment of COVID-19 variants

Shares of micro-cap biopharma Immunome Inc (NASDAQ: IMNM) are indicated to open Thursday's session sharply higher. What Happened: Immunome, which focuses on developing antibody therapies, said its discovery engine has isolated potent antibodies capable of neutralizing several SARS-CoV-2 variants, including the South African Variant  B.1.351, in pseudovirus testing.

Immunome Shares Spike 150% Higher On Coronavirus Antibody Discovery

The stock price of Immunome Inc (NASDAQ: IMNM) is trading at over 170% pre-market. This is why it happened.

IMNM Stock Price Increases Over 170% Pre-Market: Why It Happened

EXTON, Pa.--(BUSINESS WIRE)--Immunome announces that its discovery engine has isolated potent antibodies capable of neutralizing several SARS-CoV-2 variants

Immunome Discovers Antibodies Capable of Neutralizing Multiple SARS-CoV-2 Variants, Including the South African Variant, in Pseudovirus Testing

EXTON, Pa. & SAN DIEGO--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics, and Abzena, a partner research organization for integrated discovery to cGMP manufacturing solutions for biologics, today announced that Abzena was selected as Immunome's partner research organization for IMM-BCP-01, an investigational therapeutic antibody cocktail for the treatment

Abzena Selected by Immunome to Develop and Manufacture Antibody Cocktail for Immunome's COVID-19 Antibody Based Treatment

EXTON, Pa.--(BUSINESS WIRE)--Immunome announces the release of findings from its ongoing preclinical COVID-19 research program

Immunome's Research Reveals a Broad Super Responder Memory B Cell Response to the SARS-CoV-2 Virus

EXTON, Pa.--(BUSINESS WIRE)--Immunome appoints Richard Baron to BOD and Sandra Stoneman as Chief Legal Officer and Corporate Secretary

Immunome Provides Organizational Update: Appoints Richard Baron to its Board of Directors and Sandra Stoneman as Chief Legal Officer and Corporate Secretary

EXTON, Pa.--(BUSINESS WIRE)--Immunome Reports Third Quarter 2020 Financial Results and Significant Progress

Immunome Reports Third Quarter 2020 Financial Results and Significant Progress

EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics, with a focus on oncology and infectious diseases, including COVID-19, today announced the full exercise of the underwriters' option to purchase an additional 487,500 shares of common stock at the public offering price of $12.00 per share, resulting in additional gross proceeds of approximately $

Immunome Announces Exercise in Full and Closing of Over-Allotment Option in Initial Public Offering

Element Solutions Inc

Selecta Biosciences

Mission Produce

Pulmonx

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider buying can be an encouraging signal for potential investors, particularly when markets are near all-time highs.

Last Week's Notable Insider Buys: Element Solutions, Selecta Biosciences And More

EXTON, Pa.--(BUSINESS WIRE)--Immunome Announces Pricing of Upsized Initial Public Offering

Immunome Announces Pricing of Upsized Initial Public Offering

Immunome Aims For $30 Million U.S. IPO

Immunome Inc. set terms for its initial public offering, in which the Pennsylvania-based biopharmaceutical company focused on oncology looks to raise up to $32.5 million. The company is offering 2.5 million shares in the IPO, which is expected to price between $11 and $13 a share.

Immunome sets IPO terms, to raise up to $32.5 million

News for Immunome Stock (IMNM)